NovImmune licenses pre-clinical compound to Genentech

Tuesday 27 July 2010

At a time of intense competition in the antibody field, venture capital-backed NovImmune SA of Switzerland has secured an exclusive licensing deal with Genentech Inc for a pre-clinical compound targeting two forms of the Interleukin-17 (IL-17) family of cytokines.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland